GlobeNewswire

Global Blockchain Services Firm WACHSMAN Recruits Key Executives from Jefferies and J.P. Morgan to Lead New Strategy Division

Dela

Wachsman amplifies service offerings beyond public relations and events management with first major agency expansion

 

NEW YORK, NY, June 13, 2018 (GLOBE NEWSWIRE) -- Wachsman, one of the world's leading blockchain professional services firms, has hired senior bankers from investment banks Jefferies and J.P. Morgan to lead a new blockchain strategy and advisory division. Formerly Senior Vice President, Technology Investment Banking Group at Jefferies, Michael Chang joins Wachsman as Managing Director Strategy and will lead the firm's new Strategic Advisory Group in New York. Chang will be supported by Associate Director Franklin Bi, former Vice President and Blockchain Strategy Lead for J.P. Morgan's Blockchain Center of Excellence. Wachsman's Strategic Advisory Group will provide blockchain consulting and advisory services to Wachsman's existing clients as well as publicly-traded corporations and privately-held companies globally.

CEO David Wachsman said: "Today is a landmark occasion for our rapidly growing company. We have exceeded our clients' expectations with world-class public relations support and many of them have asked us to do more for them. With the experience and expertise that Michael and Franklin share, we now have the talent to offer a wider range of services. Subject matter expertise in this world-changing technology is extremely valuable, so we're proud to have attracted some of the brightest minds in blockchain to lead our new Strategic Advisory Group."

During his tenure at Jefferies, Chang founded and led the firm's blockchain coverage effort where he developed and executed blockchain strategies for clients ranging from large corporations, to institutional investors, to emerging blockchain companies. Prior to Jefferies, Chang was a Director in the Mergers and Acquisitions Group at Bank of America Merrill Lynch and Vice President at Citigroup, where he advised on over $40 Billion in M&A and capital raising transactions. Michael holds a Master of Business Administration from Cornell University, where he was a Roy H. Park Leadership Fellow.

Wachsman Managing Director Strategy, Michael Chang said: "I'm honored to bring my experience advising some of the world's largest companies to Wachsman in the fastest growing industry of our generation, blockchain. We can all see the growth trajectory for blockchain and digital assets, but organizations seldom have the experience to guide companies through how to best employ the technology. The Strategic Advisory Group will advise companies on how to accelerate their strategic objectives utilizing blockchain technology to better reach and serve their customers in new and exciting ways."

Franklin Bi spent four years at J.P. Morgan leading business strategy and use case prioritization for blockchain initiatives across wholesale banking, custody and fund services, and capital markets. Bi was responsible for driving J.P. Morgan's initial assessment of the impact of blockchain technology in 2015, co-authored the J.P. Morgan report, "Unlocking Economic Advantage with Blockchain," and played a key role in initiatives such as J.P. Morgan's Quorum project, crypto-asset strategy, and consortia engagement. Bi graduated from The Wharton School at the University of Pennsylvania with a Bachelor of Science in Economics.

Wachsman was founded by David Wachsman in December 2015 and has grown to employ 90 staff worldwide, with a client portfolio of some of the largest and indispensable companies and projects in the blockchain ecosystem, including CoinDesk, eToro, Dash, tZERO, Steemit, Bitfinex, Crypto Valley Association, and Lisk.


###

 

About Wachsman:

Wachsman is a leading professional services firm for the blockchain industry. Originally founded as a Public Relations agency in December 2015, Wachsman has expanded its service offerings to include Event Management and Strategic Advisory. The Strategic Advisory Group will be led by former Senior Vice President of Jefferies' Blockchain Coverage Group, Michael Chang, and supported by former Vice President and Blockchain Strategy Lead at J.P. Morgan's Blockchain Center of Excellence, Franklin Bi. Since the company's founding, Wachsman has grown to 90 people with offices in New York City and Dublin. The firm has represented more than 100 blockchain-focused companies, including some of the largest brands in the industry. David Wachsman is the Founder and CEO of Wachsman. Emma Walker is the Managing Director of Wachsman Europe.



Amanda Woodward
Wachsman 
917-900-2738
amanda@wachsman.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Wachsman via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen

Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum